What is ARA-290?
ARA-290 is a synthetic peptide consisting of 11 amino acids and derived from a region of the erythropoietin (EPO) molecule. It was developed to investigate tissue-protective and anti-inflammatory signalling associated with EPO while avoiding the strong red-blood-cell-producing activity for which erythropoietin is best known.
Research into ARA-290 has included cellular and animal models as well as early human clinical studies. Particular areas of investigation include inflammatory signalling, nerve biology and small-fibre neuropathy.
What is cibinetide?
Cibinetide is the name subsequently used during the clinical development of ARA-290. The terms ARA-290 and cibinetide therefore generally refer to the same peptide rather than two unrelated compounds.
The cibinetide name appears particularly frequently in human clinical literature, whereas ARA-290 is common in earlier experimental and preclinical research. When reviewing the evidence, searching both names can therefore provide a more complete picture of the peptide's research history.
Relationship to erythropoietin
Erythropoietin is a naturally occurring glycoprotein hormone best known for regulating red blood cell production. However, EPO has also been investigated for signalling effects in tissues exposed to inflammation, injury and metabolic stress.
ARA-290 was designed from a specific region of the EPO molecule associated with these proposed tissue-protective effects. Importantly, ARA-290 is not erythropoietin itself and was developed specifically to separate this signalling research from EPO's conventional erythropoietic activity.
This distinction is fundamental when interpreting studies involving the peptide.
Tissue-protective receptor research
A major focus of ARA-290 research concerns a proposed receptor complex often described in the literature as the innate repair receptor or tissue-protective receptor.
This signalling system has been proposed to involve the erythropoietin receptor (EPOR) together with the beta common receptor (βcR/CD131). Experimental research has investigated whether ARA-290 can interact with this pathway and influence cellular responses to inflammatory or tissue stress.
The precise biology and significance of this receptor model continue to be investigated, so mechanistic findings should be distinguished from demonstrated clinical outcomes.
Inflammatory signalling
ARA-290 has been investigated in experimental models involving inflammatory signalling and cellular responses to tissue stress. Studies have examined pathways associated with cytokine production, immune-cell activity and cellular protection.
Rather than functioning as a conventional broad anti-inflammatory compound, the research hypothesis surrounding ARA-290 focuses on modulation of signalling associated with injury and repair.
Effects observed in individual laboratory or animal models depend on the tissue, disease model and inflammatory stimulus being studied and cannot automatically be generalised to humans.
Neurological and small-fibre research
One of the more developed areas of cibinetide research concerns small nerve fibres. Small-fibre neuropathy involves damage or dysfunction affecting thinly myelinated and unmyelinated peripheral nerve fibres responsible for functions including pain, temperature sensation and aspects of autonomic signalling.
Human studies have investigated cibinetide in conditions associated with small-fibre loss or dysfunction, including sarcoidosis-related small-fibre neuropathy. Researchers have examined outcomes such as symptoms, functional measures and changes in corneal nerve fibres measured using specialised imaging techniques.
These studies provide human evidence but do not establish cibinetide as a generally effective treatment for neuropathy or neurological disease.
Preclinical evidence
Preclinical ARA-290 research includes cellular experiments and animal models involving inflammation, nerve injury, metabolic stress and tissue damage.
These studies have helped researchers investigate the proposed relationship between the peptide, EPO-derived signalling and tissue-protective pathways. Animal experiments can also examine biological interactions that cannot easily be reproduced in isolated cells.
However, positive findings in an animal disease model do not establish equivalent efficacy in humans. Differences in physiology, experimental conditions and disease mechanisms must be considered when translating preclinical findings.
Human clinical research
Cibinetide has progressed into human clinical investigation, including studies involving sarcoidosis-associated small-fibre neuropathy and other conditions in which inflammation or nerve dysfunction is relevant.
Some studies have reported changes in neurological or patient-reported endpoints, while research has also examined objective measures such as corneal nerve-fibre characteristics.
These findings make cibinetide notable among experimental peptides because human data exist, but the evidence remains specific to the populations, formulations, study designs and endpoints investigated. Clinical investigation should not be confused with broad regulatory approval or proof of effectiveness for unrelated conditions.
Evidence limitations
ARA-290 has an evidence base extending from mechanistic research to human studies, but the strength of evidence differs substantially between proposed effects.
The tissue-protective receptor model provides a mechanistic framework for much of the research, but demonstrating receptor-related activity does not by itself establish a therapeutic effect. Likewise, results from particular neuropathy studies cannot automatically be generalised to other neurological or inflammatory conditions.
Evidence involving pharmaceutical-grade cibinetide in controlled research should also not automatically be applied to independently produced materials labelled ARA-290.
Frequently asked questions
Are ARA-290 and cibinetide the same peptide?
Yes. Cibinetide is the name used during development of the peptide originally known as ARA-290.
Is ARA-290 the same as erythropoietin?
No. ARA-290 is an 11-amino-acid peptide derived from a region of the much larger erythropoietin molecule.
Does ARA-290 stimulate red blood cell production like EPO?
ARA-290 was specifically developed to investigate EPO-associated tissue-protective signalling without reproducing EPO's conventional erythropoietic activity.
What is the innate repair receptor?
The innate repair receptor is a proposed receptor complex associated with tissue-protective signalling. Research commonly describes it as involving EPOR and the beta common receptor, CD131.
Why is cibinetide studied in small-fibre neuropathy?
Experimental and clinical research has investigated whether signalling associated with cibinetide can influence small nerve fibres and inflammatory processes relevant to certain neuropathies.
Has ARA-290 been studied in humans?
Yes. Under the name cibinetide, the peptide has undergone human clinical investigation. This provides more direct evidence than cellular or animal experiments, but results remain specific to the particular conditions and outcomes studied.
Scientific references
Scientific literature on ARA-290 should also be searched under the name cibinetide. Relevant research includes studies of erythropoietin-derived tissue-protective signalling, the proposed innate repair receptor, inflammatory pathways, preclinical nerve models and human investigations involving small-fibre neuropathy. Findings should be interpreted according to the exact peptide preparation, model, population and endpoint studied.